Navigation Links
Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
Date:6/2/2009

eclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. BiTE antibodies targeting CEA, MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of blinatumomab and other product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, the risk that additional information relating to the safety, efficacy or tolerability of our product candidates may be discovered upon further analysis of preclinical or clinical trial data, the risk that we or our collaborators will not obtain approval to market our product candidates, the risks associated with relianc
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
2. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
3. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
4. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
5. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
6. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
7. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
8. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
9. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
10. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
11. Micromet to Present at the BIO CEO and Investor Conference on February 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 25, 2014 The report “Service Quality ... Type & Provider Type - Global Advancements, Worldwide Forecasts ... an in-depth analysis and forecasting of revenues. , ... 221 pages and in-depth TOC on “Service Quality Management ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
(Date:12/24/2014)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... hypothermic storage and cryopreservation freeze media and ... ("BioLife" or the "Company"), today announced that it will hold ... (the "Annual Meeting"). Because the expected date for ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Technologies, Inc. announced this week that it has finalized ... in Avegno for exclusive distribution rights of the AcceleDent™ ... AcceleDent™ System is currently being sold outside the USA ... The lightweight appliance, used to speed up the rate of orthodontic ...
... New York, November 21, 2011 New Report ... to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures ...   Published by  GBI Research . ... to 2017 - Glaucoma and Cataract Surgery Devices, Minimally ...
... 21, 2011 The report " ... Myeloid Leukemia) Pipeline Assessment & Global Market Forecast (2010 ... major market drivers, restraints, and opportunities in North America, ... tables and in-depth TOC on Leukemia Therapeutics Market (Acute/Chronic ...
Cached Biology Technology:OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy 2OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy 3ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 2ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 3ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market 4MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 2MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020 3
(Date:12/17/2014)... SM announced today its completion of a Good ... current U.S. Food and Drug Administration (FDA) regulations. This ... smart phone application trials utilizing the highest principles for ... determined to improve global healthcare access, quality, and delivery ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... that crystals form the basis for the penetrating icy blue glare ... solar energy technology? Crystals are at the heart of diodes. ... manufactured to form alloys, such as indium gallium nitride or InGaN. ... in the visible range, and of laser diodes (LDs) in the ...
... Ore. -- (Oct. 25, 2013) -- Twenty grams of essential amino ... weeks after knee-replacement surgeries helped 16 patients, mean age 69, recover ... ingesting a placebo. The approach -- detailed in a paper ... the Journal of Clinical Investigation -- could spell relief ...
... the region? A recent study, published in the open access ... obtain empirical data on the activity and distribution of the ... of Fiji and examine its association with the invasive creeping ... the invasive creeping daisy could in fact have a positive ...
Cached Biology News:ASU, Georgia Tech create breakthrough for solar cell efficiency 2Oregon researchers say supplement cuts muscle loss in knee replacements 2Oregon researchers say supplement cuts muscle loss in knee replacements 3Oregon researchers say supplement cuts muscle loss in knee replacements 4Angel or demon: Can a potentially invasive plant bring a positive influence to a region? 2
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
... The Caliper Sciclone ALH 3000 workstation ... diagnostic applications, from Genomic and Proteomic Sample ... Assays. The modular design of the ... options and accessories to perfectly meet the ...
General description: MaxiSorp TM surface is ideal for arraying molecules with mixed hydrophilic/hydrophobic domains such as proteins ID clarifier: Maxisorp(tm) with lid...
... Workstation from Caliper represents a revolutionary breakthrough ... first time the ability to generate real-time ... changing conditions. In addition, each channel ... to changes in temperature, and offers its ...
Biology Products: